

### Comment from Kentaro Matsui, Managing Partner at SB Investment Advisers

We are greatly resonated by AIM's noble vision of further advancing Japan's world-leading endoscopic medicine and saving the precious lives of cancer patients around the world. AIM's software, built with the cooperation of leading hospitals nationwide and KOLs, has the potential to demonstrate unrivaled accuracy and play an important role globally. We are thrilled to partner with AIM and hope that potential collaboration among the SoftBank Group, SoftBank Corp, and SVF 1 and 2 portfolio companies will support new innovations.

#### Comment from Yasuyuki Imai, Representative Director & COO, SoftBank Corp.

A 5G-based joint trial conducted last year\* marked the beginning of our collaboration with AIM. Now, with this new investment from SoftBank Vision Fund 2, we at SoftBank Corp. hope to further deepen our partnership with AIM to digitally transform Japan's medical industry. We fully identify with CEO Tomohiro Tada's vision of an endoscopic medical platform that enables patients to receive world-class endoscopic care anywhere by networking multiple endoscopy laboratories. Through our partnership with AIM, we will work to bring his vision closer to reality so the development of endoscopic medicine helps save patients' lives around the world.

#### Comment from Satoshi Fukushima, Director at Globis Capital Partners

We are happy to know that AIM, led by CEO Dr. Tomohiro Tada, will receive strong support helpful in expanding its business from Japan to the globe. Our decision to support AIM in this mission was driven by the confidence that we have in AIM to grow and refine its business offerings in furtherance of its noble mission, saving lives around the world with a novel technology first developed in Japan.

## Comment from Masataka Matsumoto, General Partner & Co-Founder at WiL, LLC.

Even though Japan is already a world leader in endoscopic medicine, I believe that AIM's focus on developing technology for solutions to global medical issues will help further strengthen Japan's position. I am convinced that AIM's mission of detecting GI cancers early will be realized, and all of us at the World Innovation Lab are excited to continue to support AI Medical on its journey.

## Comment from Yusuke Murata, General Partner at Incubate Fund

AIM has resolutely set off on its mission to expands its business globally, and we are confident that many lives will be saved through the adoption of their technology. We believe that this financing round will accelerate the timeline necessary for AIM to achieve its goals.



# Comment from Tomohiro Tada, CEO at AI Medical Service

Japan is the origin of GI endoscopy and 98% of the global market share is occupied by Japanese manufacturers (Olympus, Fuji Film, Pentax). The technical skill of Japanese endoscopists is regarded as the world's best and more than 17 million high-quality endoscopic exams are conducted in Japan each year. Therefore, training AI using large amounts of high-quality Japanese data is sure to lead to meaningful global innovation.

At present, we are conducting joint research with more than 100 top-class medical institutions in Japan (including the Cancer Institute Hospital). We also have a track record of publishing world-first papers on topics such as the classification of *Helicobacter pylori*, the detection of early gastric cancer, and the detection of early esophageal cancer. Given our track record of success, we view ourselves to be the global leader in developing endoscopic AI.

Making the most of the strong support received from the SoftBank Group, we will simultaneously contribute to the advancement of endoscopic medicine and save lives around the world by increasing the chances of early-stage cancer detection. This large-scale financing round enables us to step into global stage more confidently than ever before. We aim to take on the global challenges before us through unrelenting effort in furtherance of our mission.

\* Press Release: https://www.ai-ms.com/20210326/468/